Have you been diagnosed with Acute Lymphoblastic Leukemia? Has your leukemia come back or didn't get better after your last treatment? If so, you may be able to take part in a research study to learn more about the safety of modifying your own immune cells to treat your leukemia.

Researchers are looking for current and former smokers with or without COPD to enroll in a registry to be contacted for future studies.

We are looking for patients with kidney disease and healthy controls (no kidney disease) to provide blood samples, fill out surveys, and provide health related information to help investigators learn more about how to better diagnose and treat kidney disease. The information you provide will go into a "library" of data for doctors and researchers across the world to use for research projects. If you are a kidney patient, we are able to use your information to find out if you are eligible for treatment studies/other studies in the future.

The goal of this study is to further learn how a healthy human brain changes and works, specifically at a very young age. This study will help us learn more about children's mental, emotional and behavioral development, as well as understanding the possible causes of learning disabilities and neurodevelopmental disorders. This will be done by magnetic resonance imaging (MRI) scans of the child's brain during various times of development. Not only is MRI a safe and non-invasive procedure, but there will be no medication or sedation used for this study at any point.

The purpose of this study is to learn more about three kidney diseases called nephrotic syndrome: Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN). By collecting health information and laboratory samples from individuals who have these diseases and by making this information available to researchers, we hope to gain new knowledge about these diseases and to find better treatments for them.

Patients with previous negative prostate biopsy, but still considered at risk for prostate cancer may be eligible to take part in a study where they will have have further tests performed along with their scheduled repeat prostate biopsy. These research performed tests are being evaluated in hopes of making more accurate diagnosis and reduce the need for repeat biopsies.

Have you been diagnosed with colorectal cancer? If so, you may be eligible for a research study looking at the safety of giving a combination therapy of mFOLFOX6 and Bevacizumab with or without Atezolizumab compared to Atezolizumab alone in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.

This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with

Do you have probable Dementia with Lewy Bodies (DLB), Mild Cognitive Impairment with "high likelihood" DLB, or Parkinson's Disease Dementia (PDD)? You may be able to participate in an observational study to track your disease progression and promote future research.

Do you have lymphoma that has come back, or did not get better with the last treatment you were given? If so, you might able to participate in a study to see if the study team can make modified T cells that are able to fight and kill the lymphoma cells.